Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
Saved in:
| Title: | Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine. |
|---|---|
| Authors: | Serra L; Pfizer Vaccine Emerging Markets and China Medical and Scientific Affairs, Collegeville, PA, USA., Webber C; Pfizer Vaccine Clinical Research and Development, Hurley, UK., Burman C; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA., Bueti P; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA., Gorruso M; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA., Mather S; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA. Electronic address: Susan.Mather@pfizer.com. |
| Source: | Vaccine [Vaccine] 2022 Nov 22; Vol. 40 (49), pp. 7014-7021. Date of Electronic Publication: 2022 Oct 22. |
| Publication Type: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
